DTx London Virtual

DTx London Virtual

October 20 - 22 | BST Timezone

Accelerating Digital Therapeutics into the Hands of Patients

 

In response to Covid-19, DTx London 2020 will be taking place virtually

Registration Agenda

2020 Partners

KNOWLEDGE PARTNERS
KNOWLEDGE PARTNER

We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.

The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.

We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.

Learn More

 

KNOWLEDGE PARTNER

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.

Learn More

KNOWLEDGE PARTNER

Star is a global consultancy that connects insights, strategy, design, engineering and marketing services into a seamless workflow devised to support our clients every step of the way – no matter how long or complex their journey.

Learn More

SUPPORTERS
SUPPORTER

Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.

Learn More. 

DTx London is Going Virtual

Working with the leading lights of the field, we are providing even more high-quality learning and networking opportunities than usual, but this time, through a truly interactive virtual experience.

With the recent changes in healthcare, it is now more crucial than ever to accelerate validated digital health into the hands of patients with unmet medical needs.

The time for Digital Therapeutics is now.

DTx London is Going Virtual
Key Features
Industry Meeting Point

DTx London is the meeting point of the digital therapeutics industry. Constructed with the pioneers of the industry, this next installment of DTx London will once again bring together leaders from digital therapeutics/health companies, pharma, investors, healthcare systems and more. This is your chance to be part of the crucial discussions of the industry.

Curated Learning Journey

From commercialization and clinical trials, through to integration into healthcare and the patient perspective, DTx London will provide you with a truly end-to-end learning experience. Learning is at the heart of the agenda and through a variety of dynamic formats, you will be able to accelerate your understanding of the industry in just three days.

Crucial Discussions

Digital Therapeutics have an unprecedented opportunity to improve the lives of patients with unmet medical needs in the “new normal” and beyond. The discussions at DTx London will help accelerate this development by deep-diving into the new challenges and opportunities this industry is facing due to the recent surge in interest in validated digital healthcare.

Your Virtual Experience
“What does the Virtual Platform Offer?”

Through this virtual platform comes the opportunity to personalize your experience at DTx London 2020. Seamlessly switch between sessions, hop in and out of meetings, actively or passively take part in discussions and more are all possible depending upon your goals – and with no rushing around!

“How will I Network with my Fellow Attendees?”

By going virtual, you will be able to see every audience member and instantly message them. Through the ability to book 1-2-1 meetings, virtual “hallway conversations” and open time for casual interactions the opportunity to meet your future partners and collaborators is at the heart of this event.

“What Else is on Offer?”

You will have exclusive access to content and opportunities, pre and post event. Before the event officially starts, you will be able to enter the virtual platform and start connecting with your fellow attendees. After the event, you will have access to on-demand presentations, session write-ups and other resources for six months.

“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”

Laura Kleiman - Founder and Executive Director, Cures Within Reach for Cancer

“DTx is the must attend event in our industry”

Eddie Martucci - CEO, Akili Interactive

“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”

John Spinale - General Partner, JAZZ Venture Partners

“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”

Health Data Policy Director, Novartis

“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”

Cris de Luca, Global Director, Innovation, Johnson and Johnson Technology

“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”

Mette Dyhrberg, Founder and CEO, MyMee Inc

Expert Speaker Faculty

ANAND IYER
ANAND IYER
Chief Strategy Officer
Welldoc
ANAND IYER
Chief Strategy Officer
Welldoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

JESSICA SHULL
JESSICA SHULL
European Lead
Digital Therapeutics Alliance
JESSICA SHULL
European Lead
Digital Therapeutics Alliance
BRIAN FLATLEY
BRIAN FLATLEY
Business Strategy and Engagement Director
S3 Connected Health
BRIAN FLATLEY
Business Strategy and Engagement Director
S3 Connected Health

As Business Strategy and Engagement Director at S3 Connected Health, Brian works with pharma companies to develop and deliver digital therapeutics and digital therapy management solutions that provide value to all stakeholders in the delivery of care.

With a background in pharmaceutical science and having completed a PhD focused on oncology biomarkers, Brian is passionate about driving change through collaboration and innovation. He has held numerous roles that encompass digital health and pharmacological components, is a non-executive director of the Rare Disease Nurse Network (RDNN) in the UK, and a regular speaker at events across Europe.

KIM BADEN-KRISTENSEN
KIM BADEN-KRISTENSEN
Co-Founder & Chief Executive Officer
Brain+
KIM BADEN-KRISTENSEN
Co-Founder & Chief Executive Officer
Brain+

Kim Baden-Kristensen is the CEO and Co-founder of Brain+, an award winning Danish health tech company specializing in digital therapeutics for neurorehabilitation of disorders and injuries to the Central Nervous System (CNS).
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is an expert within digital therapeutics, with particularly emphasis on neurogame-based rehabilitation and gamified behavioral therapy.

Kim holds an MSc. In Innovation Management from Copenhagen Business School, a Health Care Innovation Management degree from Harvard Business School, and a minor in Cognitive Neuroscience from Copenhagen University.

HEATHER ROXBOROUGH
HEATHER ROXBOROUGH
Partner
Optum Ventures
HEATHER ROXBOROUGH
Partner
Optum Ventures

Heather is a master synergizer, with an enthusiastic curiosity for identifying innovative technologies and approaches to tackle major health care market needs.

Heather has spent the majority of her career focused on delivering game-changing innovation. Before Optum Ventures, she was senior director of new ventures & transactions at Johnson & Johnson Innovation, London. She has over 10 years of experience in the venture capital industry, gained while working for both early stage technology funds and corporate venture groups and has invested in a broad range of opportunities from medical devices to digital and consumer health care. Heather started her career at Unilever and holds a B.S. in Biochemistry and PhD in Clinical Biochemistry both from Queen’s University, Belfast.

ALEXANDRE CAPET
ALEXANDRE CAPET
Chief Operating Officer
Voluntis
ALEXANDRE CAPET
Chief Operating Officer
Voluntis

Before joining Voluntis, Alexandre worked for over 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group’s strategic planning and M&A for France, where he strongly contributed to building the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC Paris and Sciences Po Paris. He holds a master’s degree in health economics from Paris-Dauphine University.

LANA GHANEM
LANA GHANEM
Managing Director
Hikma Ventures
LANA GHANEM
Managing Director
Hikma Ventures

Lana is the Managing Director of Hikma Ventures which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. Currently,  Lana heads the Innovation & Leadership Advisory Board (ILAB) at Hikma which consists of  young Hikma employees whom share a dedication to advancing Hikma and ensuring it is at the frontier of innovation.

Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.

DOM RABAN
DOM RABAN
CEO & Co-Founder
Xploro
DOM RABAN
CEO & Co-Founder
Xploro

Dom Raban is CEO and co-founder of Xploro, a Digital Therapeutics platform which uses augmented reality, artificial intelligence and games to help reduce the anxiety experienced by young patients going in to hospital. Dom established Xploro after his daughter had recovered from cancer treatment and he realised the importance of providing patients with information about their treatment – something that was lacking in his daughter’s experience.
Dom has been creating ‘stuff’ for over 40 years, from punk fanzines in the 1970s to content for emerging technology platforms now. He’s been in the digital space since the start, building his first website in 1995 and his first 3D virtual environment in 1996. He is also Chair of Corporation Pop, a digital innovation agency that specialises in a user-centred design approach to develop apps, games and software.

ED ADAMSON
ED ADAMSON
Director of Strategy & Insight
Star
ED ADAMSON
Director of Strategy & Insight
Star

Ed Adamson is Director of Strategy & Insight at Star and has 19 years experience of brand-led innovation. His current focus is to harness the opportunity in tech-driven change to add new value for business and his hybrid background combines industrial design with years of innovation consultancy for many of the world’s largest companies.

RANA LONNEN
RANA LONNEN
Head Search & Evaluation Strategic Venture Capital
Novartis
RANA LONNEN
Head Search & Evaluation Strategic Venture Capital
Novartis
LORENZO CONSOLI
LORENZO CONSOLI
CEO & Co-Founder
NuvoAir
LORENZO CONSOLI
CEO & Co-Founder
NuvoAir

Lorenzo is co-founder and CEO of NuvoAir a digital therapeutics company focused on respiratory care.
Prior to founding NuvoAir, Lorenzo worked at Novartis as Innovation Director in the Digital Solutions team. Lorenzo holds an MBA from the Wharton School, University of Pennsylvania.

MARIANNE VEIGHEY
MARIANNE VEIGHEY
Director, Head of Intelligent Pharmaceuticals
AstraZeneca
MARIANNE VEIGHEY
Director, Head of Intelligent Pharmaceuticals
AstraZeneca
EDOUARD GASSER
EDOUARD GASSER
Co-Founder & CEO
Tilak Health
EDOUARD GASSER
Co-Founder & CEO
Tilak Health

Previously Studio Director at Gameloft Madrid – a company developing and editing videogames –, Edouard is leading the Tilak Healthcare team. Before heading the Madrid Creation Studio, Edouard successively worked at Gameloft as Project Manager in Paris, then Lead Producer in New Orleans. He was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics. In 2011, he co founded Productism, a social commerce website.

EREZ RAPHAEL
EREZ RAPHAEL
CEO
Dario Health
EREZ RAPHAEL
CEO
Dario Health
MARYNE COTTY-ESLOUS
MARYNE COTTY-ESLOUS
Founder
Lucine
MARYNE COTTY-ESLOUS
Founder
Lucine
RAY PINTO
RAY PINTO
Policy and Member Relations Director
DIGITALEUROPE
RAY PINTO
Policy and Member Relations Director
DIGITALEUROPE

Ray joins DIGITALEUROPE with over 20 years of government affairs and communications experience in Brussels and across the EMEA region. Previously, he worked at Microsoft being part of the team responsible for the strategies to improve relations with governments and position the company on socio-economic issues. Ray leads the digital transformation strategy to leverage DIGITALEUROPE’s expertise in key policy areas such as data protection, media, platform and consumer issues to create an important dialogue between industries being disrupted by technology and guidance to European regulators.

Ray leads several Policy and Working Groups helping our members advance important work in areas which includes artificial intelligence, skills development and the free flow of data. Areas that will be vital to unlock the full potential in Europe to deliver jobs, prepare children in education systems to be able to exploit important technologies and ensure Europe is a leader in creating world-class technology companies.

Ray holds citizenship with both Canada and France and is a graduate of McGill University in Political Science.

ASHISH PATEL
ASHISH PATEL
Principal
Optum Ventures
ASHISH PATEL
Principal
Optum Ventures

Ash is a Principal based in the London office of Optum Ventures, a digital health-focused investment group. Before Optum Ventures, Ash served as a lead life sciences investor and Head of Research for Mercia Asset Management, one of the most active investors in the UK. Prior to this, he served as Clinical Technology Director as part of the team that launched Babylon Health, a European health tech unicorn.

He started his career as an anaesthetics and intensive care doctor in the UK where he was involved in academic research work and clinical practice. He holds a M.A. and medical degree from the University of Oxford, and is a member of the CFA Institute, London

JENNY CHRISTENSSON
JENNY CHRISTENSSON
Chief Patient Officer
Elsa Science
JENNY CHRISTENSSON
Chief Patient Officer
Elsa Science

Jenny has spent over 25 years working on patient empowerment, co-existing with Rheumatoid Arthritis since 1994 has made that inevitable. In different settings she has driven the topic and projects to move the positions forward for true patient centricity.
Proving that advocacy doesn ́t always have to be driven by a patient organization.

Jenny is currently Chief Patient Officer at Elsa Science AB and serves as a constant reminder of the importance of including patients in all steps while developing a patient empowering solution. Bridging users/patients, HCPs, academia, payors and pharma is an important part in the everyday development of the tool Elsa.

Over a period of 9 years she drove the importance of patient inclusion in development as a Patient Relations Manager at Abbott/AbbVie. Developing co-created collaborations within Immunology in Sweden, Europe and Globally.

Jenny also holds 4 consecutive titles as Swedish Champion in Para Equestrian Dressage.

ED COX
ED COX
Executive Vice President, Strategic Alliances & Head of Digital Medicine
EVERSANA
ED COX
Executive Vice President, Strategic Alliances & Head of Digital Medicine
EVERSANA

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

CIARA CLANCY
CIARA CLANCY
Founder & CEO
Beats Medical
CIARA CLANCY
Founder & CEO
Beats Medical

Dr Ciara Clancy is founder and CEO of Beats Medical, a digital therapeutics company specialising in neurological and CNS conditions.

Clancy holds a degree in Physiotherapy and a PhD in Neurosurgery outcomes. Her entrepreneurial work has been internationally recognised including selection for Forbes 30 under 30, Laureate for Europe in the Cartier Awards and a finalist in the EY Entrepreneur of the Year Awards.

BRENT VAUGHAN
BRENT VAUGHAN
Healthcare Venture Capital
Morningside Venture Capital
BRENT VAUGHAN
Healthcare Venture Capital
Morningside Venture Capital

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

FRANCESCA WUTTKE
FRANCESCA WUTTKE
Chief Digital Officer
Almirall
FRANCESCA WUTTKE
Chief Digital Officer
Almirall

Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall.

Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia.

Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organisation as well as managing the strategy and commercialisation for the existing portfolio of cell therapy assets.

Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.

JUNAID BAJWA
JUNAID BAJWA
Chief Medical Scientist
Microsoft
JUNAID BAJWA
Chief Medical Scientist
Microsoft

Dr Junaid Bajwa is a practicing physician, the Global Lead for Strategic Alliances + Solutions for the Global Digital Centre of Excellence at MSD. Academically he is a Visiting Scientist at the Harvard School of Public Health, and a Clinical Associate Professor at UCL, London.

He has been interested in the use of technology and data to improve patient outcomes for many years, and has worked with NHS England, and Verily (part of Google’s Alphabet parent organisation) on projects involving AI and data analytics. Junaid has worked in primary care as a physician and in the payer, provider and regulatory markets within the UK where he specialized in informatics, digital transformation, and leadership. He has consulted for health care systems across the US, Australia, New Zealand, Singapore, and Europe, in addition to being seconded by the NHS to work with IBM.

EDWARD KLIPHIUS
EDWARD KLIPHIUS
Investment Director
M Ventures
EDWARD KLIPHIUS
Investment Director
M Ventures
ELENA MUSTATEA
ELENA MUSTATEA
Chief Executive Officer
Bold Health
ELENA MUSTATEA
Chief Executive Officer
Bold Health

Elena Mustatea is Co-founder and CEO of Bold Health, a startup developing digital therapeutics for functional and autoimmune conditions, leveraging behavioural medicine and machine learning to deliver personalised and highly effective treatments and self management support. Elena was named Forbes’ Europe 30 Under 30 Finance List in 2018 in her role as venture capital investor with leading European VC fund Atomico, and previously also worked in investment banking at J.P. Morgan and Goldman Sachs, management consulting at Oliver Wyman, and ran a media business.

DEREK RICHARDS
DEREK RICHARDS
Chief Science Officer
SilverCloud Health
DEREK RICHARDS
Chief Science Officer
SilverCloud Health
ACACIA PARKS
ACACIA PARKS
Chief Scientist
Happify
ACACIA PARKS
Chief Scientist
Happify

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

MAROOF AHMED
MAROOF AHMED
Co-Founder & COO
Quit Genius
MAROOF AHMED
Co-Founder & COO
Quit Genius

Dr. Maroof Ahmed is a medical doctor who graduated from Imperial College London with dual degrees in Medicine and Business Management. He is the co-founder and COO of Digital Therapeutics.

Maroof spent 4 years conducting academic research in the fields of neurology, behavioural change, digital health and smoking cessation. He has published multiple peer-reviews papers on these topics and also acts as a reviewer for JMIR.

Whilst training to become a doctor, Maroof saw the impact smoking had on the lives of the patients around him and wanted to make a difference. So together with his co-founders, they put on hold their clinical careers to pursue Quit Genius full-time. This was a tough decision but they made this choice as it will allow them to make an impact on the lives of people worldwide at scale.

STEVE BURNS
STEVE BURNS
VP, Product Development & Digital Therapeutics
AstraZeneca
STEVE BURNS
VP, Product Development & Digital Therapeutics
AstraZeneca
CARMEN RIOS
CARMEN RIOS
VP, International
Limbix
CARMEN RIOS
VP, International
Limbix

Carmen is an expert in digital transformation, having worked in a variety of high-pressure roles in technology as an entrepreneur & setting up international operations for Blue-Chip companies.

She currently leads the International efforts of Limbix, a Sequoia-backed startup building a pipeline of prescription digital therapeutics that combine the use of Virtual Reality (VR) & mobile apps to deliver cognitive-behavioural therapy to treat mental health conditions. The company has become the leader in the Digital Mental Health space thanks to its partnerships with top universities and hospitals.

Fluent in six languages and all about helping businesses contribute to a better world. Carmen is also passionate about bringing people together through her love of Spanish food.

CHARLOTTE LEE
CHARLOTTE LEE
Director
Big Health
CHARLOTTE LEE
Director
Big Health
DENNIS HERMANN
DENNIS HERMANN
VP, Business Development & Corporate Finance
Kaia Heath
DENNIS HERMANN
VP, Business Development & Corporate Finance
Kaia Heath

Dennis is VP of business development & corporate finance at Kaia Health, a start-up developing individualised digital therapies for chronic diseases with a focus on backpain and respiratory conditions.
Prior to joining Kaia Health, Dennis was the COO of Oro de Cacao, where he led the scale-up process and financing rounds, and advised clients on Private Equity and Real Estate investments at 1875 FINANCE.

ALI HASAN
ALI HASAN
Chief Medical & Healthcare officer
Vitality
ALI HASAN
Chief Medical & Healthcare officer
Vitality
DONNA WALSH
DONNA WALSH
Executive Director
EFNA
DONNA WALSH
Executive Director
EFNA

Donna became the Executive Director of EFNA in June 2012. Donna’s training is in Journalism, but she has worked with patient organisations in the neurological sector – in various roles – since leaving university. This included work with the European Migraine and Headache Alliance [EMHA] and the Migraine Association of Ireland [MAI], as well as being a representative to the Neurological Alliance of Ireland. Donna oversees the strategic direction of EFNA and leads in the creation and implementation of its annual workplan, projects and activities. Since joining EFNA, Donna has led the development of some of EFNA’s current keynote initiatives such as its MEP Interest Group on Brain, Mind and Pain and Training Initiatives for Neurology Advocates. She is also active in representing EFNA and the neurology patient community externally, including as a current Board Member of the European Brain Council and as a Member of the European Academy of Neurology’s European Affairs Sub-Committee.

HAKIM YADI
HAKIM YADI
Co-Founder & CEO
Closed Loop Medicine
HAKIM YADI
Co-Founder & CEO
Closed Loop Medicine

Hakim is a Co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.

As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health – and therefore wealth and well-being -outcomes.

Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.

Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration.

Hakim started his career at PA Consulting, where he co-managed the company’s translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).

He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.

TRYGGVI THORGEIRSSON
TRYGGVI THORGEIRSSON
CEO & Co-Founder
Sidekick Health
TRYGGVI THORGEIRSSON
CEO & Co-Founder
Sidekick Health
MALA MAWKIN
MALA MAWKIN
Doctor
Southend University Hospital NHS Trust Foundation
MALA MAWKIN
Doctor
Southend University Hospital NHS Trust Foundation

Dr Mala Mawkin MBBS, BSc (Hons), FICSM is an award winning medical doctor who trained at Imperial College London. Mala has previously worked with institutions such as the European Space Agency, Harvard University and several London Medical Technology companies. Mala was a Trustee for the century old Medical Women’s Federation UK for 3 years, listed on the Tech London 25 Under 25 and was one of two in her graduating cohort of 300 to be awarded a Fellowship of Imperial College School of Medicine. She is currently an appointed Council Member for the Royal Society of Medicine Digital Health Council.

Mala was featured on the Forbes 30 Under 30 list for Science & Healthcare, and also on Forbes 30 Under 30 Europe Youngest list. She was featured in 2018 Vogue Magazine as 10 Rising Female Stars for a feature publication with Nike and Naomi Campbell. Mala was also interviewed by Makers for a Barbie Be Inspired #closethedreamgap workshop for Women in Science. In 2019, Mala was selected as a “highly commended” finalist at the UK Women of the Future Awards.

Mala won the grand prize in a national competition run by the UK Space Agency for work discussing the future of space flight. From this, she was invited to NASA for 10 days. Mala was a runner up in the AXA Ambition Awards for Science and was awarded £10,000. Mala completed a 3 month medical research project at the European Space Agency (ESA), Germany. There she investigated glucose tolerance in European astronauts that flew in Shuttle missions. She then presented her work at Imperial and the UK Space Agency.

For her volunteer work Mala was awarded the Imperial College School of Medicine Alumni Award for Pastoral, Charitable and Community. She was also awarded Young Volunteer of the Year by her local council.

She has worked for leading medical technology startups in London as well as working with brands such as Unilever, Microsoft Health and Uber. Mala is a keen writer and has written as an official blogger for Imperial College London for 6 years, was The Times student ambassador and has written feature articles for The Guardian.

Mala has a BSc in Global Health and furthered her interest by undertaking an e-health research project in Malawi, and later presented the work internationally. She has also worked within the Digital Health team at Harvard University & Boston Children’s Hospital. Mala has co-authored research papers in anaesthesia in extreme environments providing considerations for future space exploration missions as well as research in medical technology for surgery training.

MATTHIAS ZENKER
MATTHIAS ZENKER
Partner
GAIA AG
MATTHIAS ZENKER
Partner
GAIA AG

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

COLIN ESPIE
COLIN ESPIE
Co-Founder & CMO
Big Health
COLIN ESPIE
Co-Founder & CMO
Big Health

Workshops - Tuesday, October 20th

  • Workshop 1: The Business of Digital Therapeutics
  • Workshop 2: A Deep Dive into the European Regulatory Landscape
Workshop 1: The Business of Digital Therapeutics
Workshop Leaders

Matthias Zenker, Partner, GAIA AG
Kim Baden-Kristensen, Co-Founder & CEO, Brain+

9:00am
Presentation: An Inside Look at the Business of Digital Therapeutics
  • A brief overview of the various business models adopted by digital therapeutic companies
  • An insight into the various routes to market
  • Can DTx companies exist with both regulated and Non-regulated therapeutics or do you have to “pick a side”
9:30am
Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • What are the current business models being used within the industry and which are demonstrating the most success?
  • How do some business models favour certain types of digital therapeutic over others?
  • What are the route to market opportunities available to the DTx industry?
10:30am
Refreshment Break
11:00am
Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised, via interactive polls, during this collaborative discussion.

Leave this workshop with:

  • A deeper understanding of the various business models demonstrated by digital therapeutic companies
  • Up-to-date information on business models of varying successes in the current industry
  • An understanding of the current successes of business models in varying countries across Europe
  • A clear understanding of current routes to market and their intricacies
  • Your questions answered by industry leaders and your peers
12:00pm
End of Workshop 1
Download Agenda
Workshop 2: A Deep Dive into the European Regulatory Landscape
Workshop Leaders

Jessica Schull, European Lead, Digital Therapeutics Alliance

Ray Pinto, Policy and Member Relations Director, DIGITALEUROPE

1:00pm
Presentation: A Top Level View of the European Regulatory Landscape - The Old & The New
  • A look at the current standards of regulation across Europe for digital therapeutics
  • What are some of the new regulatory standards being introduced into Europe and how does it affect DTx?
  • How can DTx companies best connect and work with regulatory bodies for success across Europe?
1:40pm
Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the regulatory landscape across Europe and hear views on how best to interact with the regulatory bodies. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • How does regulation for digital therapeutics differ from country to country across Europe?
  • Is it possible to achieve pan-European digital therapeutics regulation?
  • How do the new Medical Device Regulation updates affect achieving regulatory approval for digital therapeutics?
2:30pm
Refreshment Break
3:00pm
Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised, via interactive polls, during this collaborative discussion.

Leave this workshop with:

  • A clear understanding of the European regulatory landscape
  • A deeper understanding of how best to tackle the varying Regulatory bodies across Europe
  • An understanding of how the new MDR changes will affect the DTx industry and how best to adhere to them
  • Being in the know for future plans for a pan-European regulation for digital therapeutics
  • Your questions answered by industry-leading experts and your peers
4:00pm
End of Workshop 2
Download Agenda

Summit Agenda

  • Day 2: Wednesday, October 21st
  • Day 3: Thursday, October 22nd
Day 2: Wednesday, October 21st
8:00am
Registration, Breakfast & Networking
9:00am
Chairs Opening Remarks & Setting the Scene

Ciara Clancy, Founder & CEO, Beats Medical

9:10am
Presentation: Big Health & the NHS

Colin Espie, Co-Founder & CMO, Big Health

9:50am
Panel Discussion & Interactive Q&A: Digital Therapeutics in the Covid-19-Impacted Healthcare Systems

Kim Baden-Kristensen, Co-Founder & CEO, Brain+
Brent Vaughan, Healthcare Venture Capital, Morningside Venture Capital
Charlotte Lee, Director, Big Health
Marianne Veighey, Director, Head of Intelligent Pharmaceuticals, AstraZeneca

10:40am
Morning Refreshments and Networking

Grab your coffee or tea and virtually meet up with folks from across the audience, whether it’s for a pre-booked meeting, casual chat, or anything in-between, the choice is yours.

Day 1 will now Split into 2 tracks

DTx London will now split into two tracks, whilst keeping open the opportunity for networking and 1-2-1 meetings.

Personalize your experience by hopping in and out of sessions and meetings seamlessly.

Track 1

Deciphering Growth & Commercialisation for Digital Therapeutics

Chair: Ciara Clancy, Co-Founder & CEO, Beats Medical

11:30am
Presentation: Scaling across the EU - Challenges, Barriers and Successes

Acacia parks, Chief Scientist, Happify

11:55am
Fireside Chat: The Regulatory Story within the European Landscape

Jessica Shull, European Lead, Digital Therapeutics Alliance
Dennis Hermann, VP, Business Development, Kaia Health

Track 2

Front Line Considerations for Digital Therapeutics

Chair: Elena Mustatea, Chief Executive Office, Bold Health

11:30am
Presentation:  It's Not Good Enough to have a Good Intervention

Derek Richards, Chief Science Officer, SilverCloud Health

11:55am
Panel Discussion & Interactive Q&A: From Clinic to Clinician - Achieving Adoption at Scale in the Clinic

Edouard Gasser, Chief Executive Officer, Tilak Healthcare
Hakim Yadi, Co-Founder & CEO, Closed Loop Medicine
Mala Mawkin, Medical Doctor, Southend University Hospital NHS Trust Foundation

12:35pm
Lunch and Networking

At last, an actual meal of your choice at a conference! Enjoy your lunch whilst connecting with old friends or new folks you have met from your interactions so far.

2:00pm
Presentation: Scale, Expansion and Partnerships - A Case Study by NuvoAir

Lorenzo Consoli, CEO & Founder, NuvoAir

2:25pm
Panel Discussion & Interactive Q&A: How to Commercialize Across Europe and is Pharma the Key?

Alexandre Capet, Chief Operating Officer, Voluntis
Francesca Wuttke, Chief Digital Officer, Almirall
Tryggvi Thorgeirsson, Co-Founder & CEO, Sidekick Health
Junaid Bajwa, Chief Medical Scientist, Microsoft

2:00pm
Presentation: User-Centric Solutions to Drive Satisfaction, Engagement and Outcomes

Erez Raphael, Chief Executive Officer, Dario Health

2:25pm
Panel Discussion & Interactive Q&A: Serving the Patient: It’s Not About Us, Without Us

Donna Walsh, Executive Director, EFNA
Dom Raban, CEO & Co-Founder, Xploro
Marianne Veighey, Director, Head of Intelligent Pharmaceuticals, AstraZeneca
Jenny Christensson, Chief Patient Officer, Elsa Science

3:05pm
Afternoon Refreshments and Networking

Catch-up with peers, pre-booked 1-2-1 meetings, making new connections, all are on the table.

4:05pm
Panel Discussion & Interactive Q&A: How Should we Leverage Real World Evidence in the “New Normal”

Erez Raphael, Chief Executive Officer, Dario Health
Steve Burns, VP, Product Development & Digital Therapeutics, AstraZeneca
Elena Mustatea, Chief Executive Officer, Bold Health
Ali Hasan, Chief Medical & Healthcare Officer, Vitality

4:45pm
Chairs Closing Remarks

Ciara Clancy, Founder & CEO, Beats Medical

5:00pm
Virtual Drinks Reception

Grab a glass of wine, beer or whichever drink you choose as you catch-up with old friends and make new connections, either 1-2-1 or in groups. Just because we are virtually meeting, doesn’t mean we can’t enjoy a one or two (or more) drinks together!

?:??pm
“Close of Day 2”

We say “Close of Day 2” but it’s not really the end of the day as the conference platform will remain open so that you can keep the interactions rolling.

Download Agenda
Day 3: Thursday, October 22nd
8:00am
Breakfast and Networking

Have your Thursday morning breakfast whilst reconnecting with your new connections from the Summit so far.

9:00am
Chairs Opening Remarks and Setting the Scene

Edouard Gasser, Chief Executive Officer, Tilak Healthcare

9:10am
Presentation: Presentation Title TBA

Brent Vaughan, Healthcare Venture Capital, Morningside Venture Capital

9:40am
Panel Discussion & Interactive Q&A: What do Investors Really Think About Digital Therapeutics?

Rana Lonnen, Head Search & Evaluation Strategic Venture Capital, Novartis

Edward Kliphius, Investment Director, M Ventures

Heather Roxborough, Partner, Optum Ventures

Lana Ghanem, Managing Director, Hikma Ventures

10:30am
Morning Refreshments and Networking

Share a tea or coffee (virtually) with folks from across the industry.

11:15am
Presentation: Commercialising Digital Therapeutics for Neurological and CNS Conditions

Ciara Clancy, Founder & CEO, Beats Medical

11:45am
Presentation: The Effectiveness of a Novel Digital Tobacco Cessation Program with Carbon Monoxide Monitoring with US Employers

Maroof Ahmed, Co-Founder & COO, Quit Genius

12:15am
Presentation: Presentation by Lucine

Maryne Cotty-Eslous, Founder, Lucine

12:45pm
Lunch and Networking

Enjoy another lunch of your choosing as you make those final connections.

2:00pm
Panel Discussion & Interactive Q&A: Choosing the ‘Right’ Business Model for You

Moderated by Ed Cox, Executive Vice President, Strategic Alliances & Head of Digital Medicine, EVERSANA

Matthias Zenker, Partner, GAIA AG

Carmen Rios, VP, International, Limbix

Ashish Patel, Principal, Optum Ventures

2:50pm
Chairs Closing Remarks

Edouard Gasser, Chief Executive Officer, Tilak Healthcare

3:00pm
End of DTx London 2020

Roll straight into the rest of your Thursday, with no flight to catch!

Download Agenda

Partnerships

Like you, here at GreyGreen we are adapting our plans in response to the ‘new normal’.  As experts in curating fantastic audiences, we know that people still want to meet to learn and network with each other. The only difference is the “venue”.

As you adapt your marketing strategy, the same questions remain, how do you reach new prospects, demonstrate your capabilities, and build brand awareness? With GreyGreen you can be assured that our summits, either face to face or virtual, will deliver the audience you need to reach.

Connecting with your customer base has never been easier. We’ll bring our expertise to the table, advising you on how best to deliver your messaging and helping you prepare for the online experience. We use World-class software to ensure our summits are the best they can be.

Contact Us +
Partnerships

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration